Top

Clinical and Translational Oncology

Published in:

01-07-2020 | Prostate Cancer | Research Article

Role of novel hormonal therapies in the management of non-metastatic castration-resistant prostate cancer: a literature-based meta-analysis of randomized trials

Authors: G. Roviello, M. R. Gatta Michelet, A. D’Angelo, S. Nobili, E. Mini

Published in: Clinical and Translational Oncology | Issue 7/2020

Abstract

Background

Novel hormonal therapies have been recently investigated in non-metastatic castration-resistant prostate cancer (CRPC). We performed a meta-analysis to assess the efficacy and safety of novel hormonal therapies in non-metastatic CRPC.

Materials and methods

The primary outcome was metastasis-free survival (MFS). The secondary endpoints were overall survival (OS), time to PSA progression and safety. We planned a subgroup analysis according to the PSA doubling time (> 6 vs < 6 months), Eastern Cooperative Oncology Group (ECOG) performance status (1 vs 0) and concomitant use of bone-targeting agent (yes vs no).

Results

Pooled analysis of novel hormonal therapies revealed significantly increased MFS compared with placebo (hazard ratio (HR): HR = 0.32, 95% CI 0.25–0.41; p < 0.00001). The subgroup analysis showed a statistically significant MFS advantage in favour of men with the lower ECOG performance status. Other secondary endpoints favoured the novel hormonal therapies. The relative risk (RR) of grade ≥ 3 adverse events and ≥ 3 hypertension was 1.31 and 1.39, respectively.

Conclusions

This study confirmed the efficacy and safety of the novel hormonal therapies in non-metastatic CRPC.

Available only for authorised users

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin Am Cancer Soc. 2018;68:7–30. https://doi.org/10.3322/caac.21442.CrossRef

Mottet N, Bellmunt J, Bolla M, Briers E, Cumberbatch MG, De Santis M, et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2017;71:618–29. https://doi.org/10.1016/j.eururo.2016.08.003.CrossRefPubMed

Neppl-Huber C, Zappa M, Coebergh JW, Rapiti E, Rachtan J, Holleczek B, et al. Changes in incidence, survival and mortality of prostate cancer in Europe and the United States in the PSA era: additional diagnoses and avoided deaths. Ann Oncol Off J Eur Soc Med Oncol. 2012;23:1325–34. https://doi.org/10.1093/annonc/mdr414.CrossRef

Anantharaman A, Small EJ. Tackling non-metastatic castration-resistant prostate cancer: special considerations in treatment. Expert Rev Anticancer Ther. 2017;17:625–33. https://doi.org/10.1080/14737140.2017.1333903.CrossRefPubMed

Smith MR, Kabbinavar F, Saad F, Hussain A, Gittelman MC, Bilhartz DL, et al. Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. J Clin Oncol. 2005;23:2918–25. https://doi.org/10.1200/JCO.2005.01.529.CrossRefPubMed

Taplin M-E, Balk SP. Androgen receptor: a key molecule in the progression of prostate cancer to hormone independence. J Cell Biochem. 2004;91:483–90. https://doi.org/10.1002/jcb.10653.CrossRefPubMed

Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res. 6249s;12:6243s–9s. https://doi.org/10.1158/1078-0432.CCR-06-0931.CrossRefPubMed

Freedland SJ, Richhariya A, Wang H, Chung K, Shore ND. Treatment patterns in patients with prostate cancer and bone metastasis among US community-based urology group practices. Urology. 2012;80:293–8. https://doi.org/10.1016/j.urology.2012.04.007.CrossRefPubMed

Smith MR, Cook R, Lee K-A, Nelson JB. Disease and host characteristics as predictors of time to first bone metastasis and death in men with progressive castration-resistant nonmetastatic prostate cancer. Cancer. 2011;117:2077–85. https://doi.org/10.1002/cncr.25762.CrossRefPubMed

10.

Smith MR, Saad F, Oudard S, Shore N, Fizazi K, Sieber P, et al. Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time. J Clin Oncol. 2013;31:3800–6. https://doi.org/10.1200/JCO.2012.44.6716.CrossRefPubMedPubMedCentral

11.

Horwich A, Hugosson J, de Reijke T, Wiegel T, Fizazi K, Kataja V, et al. Prostate cancer: ESMO consensus conference guidelines 2012. Ann Oncol Off J Eur Soc Med Oncol. 2013;24:1141–62. https://doi.org/10.1093/annonc/mds624.CrossRef

12.

Scher HI, Liebertz C, Kelly WK, Mazumdar M, Brett C, Schwartz L, et al. Bicalutamide for advanced prostate cancer: the natural versus treated history of disease. J Clin Oncol. 1997;15:2928–38. https://doi.org/10.1200/JCO.1997.15.8.2928.CrossRefPubMed

13.

Lodde M, Lacombe L, Fradet Y. Salvage therapy with bicalutamide 150 mg in nonmetastatic castration-resistant prostate cancer. Urology. 2010;76:1189–93. https://doi.org/10.1016/j.urology.2009.12.057.CrossRefPubMed

14.

Suzuki H, Okihara K, Miyake H, Fujisawa M, Miyoshi S, Matsumoto T, et al. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade. J Urol. 2008;180:921–7. https://doi.org/10.1016/j.juro.2008.05.045.CrossRefPubMed

15.

Mason MD, Sydes MR, Glaholm J, Langley RE, Huddart RA, Sokal M, et al. Oral sodium clodronate for nonmetastatic prostate cancer—results of a randomized double-blind placebo-controlled trial: Medical Research Council PR04 (ISRCTN61384873). J Natl Cancer Inst. 2007;99:765–76. https://doi.org/10.1093/jnci/djk178.CrossRefPubMed

16.

Nelson JB, Love W, Chin JL, Saad F, Schulman CC, Sleep DJ, et al. Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer. Cancer. 2008;113:2478–87. https://doi.org/10.1002/cncr.23864.CrossRefPubMed

17.

Esther J, Maughan BL, Anderson N, Agarwal N, Hahn AW. Management of nonmetastatic castration-resistant prostate cancer: recent advances and future direction. Curr Treat Options Oncol. 2019;20:14. https://doi.org/10.1007/s11864-019-0611-z.CrossRefPubMed

18.

Smith MR, Saad F, Coleman R, Shore N, Fizazi K, Tombal B, et al. Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet (London, England). 2012;379:39–46. https://doi.org/10.1016/S0140-6736(11)61226-9.CrossRef

19.

Smith MR, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Graff JN, et al. Apalutamide treatment and metastasis-free survival in prostate cancer. N Engl J Med. 2018;378:1408–18. https://doi.org/10.1056/NEJMoa1715546.CrossRefPubMed

20.

Hussain M, Fizazi K, Saad F, Rathenborg P, Shore N, Ferreira U, et al. Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer. N Engl J Med. 2018;378:2465–74. https://doi.org/10.1056/NEJMoa1800536.CrossRefPubMedPubMedCentral

21.

Fizazi K, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S, et al. Darolutamide in nonmetastatic, castration-resistant prostate cancer. N Engl J Med. 2019;380:1235–46. https://doi.org/10.1056/NEJMoa1815671.CrossRefPubMed

22.

Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4:1. https://doi.org/10.1186/2046-4053-4-1.CrossRefPubMedPubMedCentral

23.

Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17:1–12. https://www.ncbi.nlm.nih.gov/pubmed/8721797.CrossRefPubMed

24.

DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88. https://www.ncbi.nlm.nih.gov/pubmed/3802833.CrossRefPubMed

25.

Cochran WG. The combination of estimates from different experiments. Biometrics. 1954;10:101. https://doi.org/10.2307/3001666.CrossRef

26.

Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–60. https://doi.org/10.1136/bmj.327.7414.557.CrossRefPubMedPubMedCentral

27.

Roviello G, Sigala S, Sandhu S, Bonetta A, Cappelletti MR, Zanotti L, et al. Role of the novel generation of androgen receptor pathway targeted agents in the management of castration-resistant prostate cancer: a literature based meta-analysis of randomized trials. Eur J Cancer. 2016;61:111–21. https://doi.org/10.1016/j.ejca.2016.04.002.CrossRefPubMed

28.

Francini E, Petrioli R, Roviello G. No clear evidence of a clinical benefit of a sequential therapy regimen with abiraterone acetate and enzalutamide. Expert Rev Anticancer Ther. 2014;14:1135–40. https://doi.org/10.1586/14737140.2014.949677.CrossRefPubMed

29.

Petrioli R, Francini E, Roviello G. Is there still a place for docetaxel rechallenge in prostate cancer? World J Clin Oncol. 2015;6:99. https://doi.org/10.5306/wjco.v6.i5.99.CrossRefPubMedPubMedCentral

30.

Afshar M, Evison F, James ND, Patel P. Shifting paradigms in the estimation of survival for castration-resistant prostate cancer: a tertiary academic center experience. Urol Oncol. 2015;33(338):e1–7. https://doi.org/10.1016/j.urolonc.2015.05.003.CrossRef

31.

Xie W, Regan MM, Buyse M, Halabi S, Kantoff PW, Sartor O, et al. Metastasis-free survival is a strong surrogate of overall survival in localized prostate cancer. J Clin Oncol. 2017;35:3097–104. https://doi.org/10.1200/JCO.2017.73.9987.CrossRefPubMedPubMedCentral

32.

Roviello G, Generali D. Is the fatigue an adverse event of the second generation of hormonal therapy? Data from a literature-based meta-analysis. Med Oncol. 2018;35:29. https://doi.org/10.1007/s12032-018-1081-z.CrossRefPubMed

33.

Iacovelli R, Verri E, Cossu Rocca M, Aurilio G, Cullurà D, De Cobelli O, et al. The incidence and relative risk of cardiovascular toxicity in patients treated with new hormonal agents for castration-resistant prostate cancer. Eur J Cancer. 2015;51:1970–7. https://doi.org/10.1016/j.ejca.2015.06.106.CrossRefPubMed

34.

Di Nunno V, Mollica V, Santoni M, Gatto L, Schiavina R, Fiorentino M, et al. New hormonal agents in patients with nonmetastatic castration-resistant prostate cancer: meta-analysis of efficacy and safety outcomes. Clin Genitourin Cancer. 2019. https://doi.org/10.1016/j.clgc.2019.07.001.CrossRefPubMed

Title: Role of novel hormonal therapies in the management of non-metastatic castration-resistant prostate cancer: a literature-based meta-analysis of randomized trials
Authors: G. Roviello
M. R. Gatta Michelet
A. D’Angelo
S. Nobili
E. Mini
Publication date: 01-07-2020
Publisher: Springer International Publishing
Keywords: Prostate Cancer
Metastasis
Prostate Cancer
Apalutamide
Enzalutamide
Darolutamide
Published in: Clinical and Translational Oncology / Issue 7/2020
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI: https://doi.org/10.1007/s12094-019-02228-2

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Background

Materials and methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 7/2020

Vitexin, an inhibitor of hypoxia-inducible factor-1α, enhances the radiotherapy sensitization of hyperbaric oxygen on glioma

Calcium-sensing receptor bridges calcium and telomerase reverse transcriptase in gastric cancers via Akt

Li–Fraumeni syndrome heterogeneity

Situation, challenges, and SEOM recommendations for the future of undergraduate education in Oncology in Spain

Updated guidelines for predictive biomarker testing in advanced non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology

Prognostic factors associated with survival in a large cohort of gastric cancer patients resected over a decade at a single Italian center: the Cremona experience

Keynote webinar | Spotlight on antibody–drug conjugates in cancer